PURPOSE: In search for more effective clinical protocols, the antimetabolite drug 5-fluorouracil (5-FU) has been successfully included in new regimens of bladder cancer combination chemotherapy. In the present study, we have investigated the effects of 5-FU treatment on apoptosis induction in wild-type and mutant p53 urinary bladder cancer cells. METHODS: We have used MTT-based assays, FACS analysis, Western blotting and semi-quantitative RT-PCR in RT4 and RT112 (grade I, wild-type p53), as well as in T24 (grade III, mutant p53) and TCCSUP (grade IV, mutant p53) human urinary bladder cancer cell lines. RESULTS: In the urothelial bladder cancer cell lines RT4 and T24, 5-FU-induced TS inhibition proved to be associated with cell type-dependent (a) sensitivity to the drug, (b) Caspase-mediated apoptosis, (c) p53 stabilization and activation, as well as Rb phosphorylation and E2F1 expression and (d) transcriptional regulation of p53 target genes and their cognate proteins, while an E2F-dependent transcriptional network did not seem to be critically engaged in such type of responses. CONCLUSIONS: We have shown that in the wild-type p53 context of RT4 cells, 5-FU-triggered apoptosis was prominently efficient and mainly regulated by p53-dependent mechanisms, whereas the mutant p53 environment of T24 cells was able to provide notable levels of resistance to apoptosis, basically ascribed to E2F-independent, and still unidentified, pathways. Nevertheless, the differential vulnerability of RT4 and T24 cells to 5-FU administration could also be associated with cell-type-specific transcriptional expression patterns of certain genes critically involved in 5-FU metabolism.
PURPOSE: In search for more effective clinical protocols, the antimetabolite drug 5-fluorouracil (5-FU) has been successfully included in new regimens of bladder cancer combination chemotherapy. In the present study, we have investigated the effects of 5-FU treatment on apoptosis induction in wild-type and mutant p53 urinary bladder cancer cells. METHODS: We have used MTT-based assays, FACS analysis, Western blotting and semi-quantitative RT-PCR in RT4 and RT112 (grade I, wild-type p53), as well as in T24 (grade III, mutant p53) and TCCSUP (grade IV, mutant p53) human urinary bladder cancer cell lines. RESULTS: In the urothelial bladder cancer cell lines RT4 and T24, 5-FU-induced TS inhibition proved to be associated with cell type-dependent (a) sensitivity to the drug, (b) Caspase-mediated apoptosis, (c) p53 stabilization and activation, as well as Rb phosphorylation and E2F1 expression and (d) transcriptional regulation of p53 target genes and their cognate proteins, while an E2F-dependent transcriptional network did not seem to be critically engaged in such type of responses. CONCLUSIONS: We have shown that in the wild-type p53 context of RT4 cells, 5-FU-triggered apoptosis was prominently efficient and mainly regulated by p53-dependent mechanisms, whereas the mutant p53 environment of T24 cells was able to provide notable levels of resistance to apoptosis, basically ascribed to E2F-independent, and still unidentified, pathways. Nevertheless, the differential vulnerability of RT4 and T24 cells to 5-FU administration could also be associated with cell-type-specific transcriptional expression patterns of certain genes critically involved in 5-FU metabolism.
Authors: D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: Pedro J Real; Cristina Sanz; Olga Gutierrez; Carlos Pipaon; Ana M Zubiaga; Jose L Fernandez-Luna Journal: FEBS Lett Date: 2006-10-02 Impact factor: 4.124
Authors: Megan M Garrity; Lawrence J Burgart; Michelle R Mahoney; Harold E Windschitl; Muhammad Salim; Martin Wiesenfeld; James E Krook; John C Michalak; Richard M Goldberg; Michael J O'Connell; Alfred F Furth; Daniel J Sargent; Linda M Murphy; Eunice Hill; Darren L Riehle; Cecelia H Meyers; Thomas E Witzig Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Christian Weiss; Dirk G Engehausen; Frens S Krause; Thomas Papadopoulos; Jürgen Dunst; Rolf Sauer; Claus Rödel Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-30 Impact factor: 7.038
Authors: M Danielle Bareford; Margaret A Park; Adly Yacoub; Hossein A Hamed; Yong Tang; Nichola Cruickshanks; Patrick Eulitt; Nisan Hubbard; Gary Tye; Matthew E Burow; Paul B Fisher; Richard G Moran; Kenneth P Nephew; Steven Grant; Paul Dent Journal: Cancer Res Date: 2011-05-27 Impact factor: 12.701
Authors: Ning Zhou; Kamini Singh; Maria C Mir; Yvonne Parker; Daniel Lindner; Robert Dreicer; Jeffrey A Ecsedy; Zhongfa Zhang; Bin T Teh; Alexandru Almasan; Donna E Hansel Journal: Clin Cancer Res Date: 2013-02-12 Impact factor: 12.531